JP2021532167A5 - - Google Patents
Info
- Publication number
- JP2021532167A5 JP2021532167A5 JP2021518029A JP2021518029A JP2021532167A5 JP 2021532167 A5 JP2021532167 A5 JP 2021532167A5 JP 2021518029 A JP2021518029 A JP 2021518029A JP 2021518029 A JP2021518029 A JP 2021518029A JP 2021532167 A5 JP2021532167 A5 JP 2021532167A5
- Authority
- JP
- Japan
- Prior art keywords
- pcsk9 inhibitor
- pharmaceutical composition
- pcsk9
- pancreatitis
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862680896P | 2018-06-05 | 2018-06-05 | |
| US62/680,896 | 2018-06-05 | ||
| PCT/US2019/035310 WO2019236528A1 (en) | 2018-06-05 | 2019-06-04 | Compositions and methods for treating pancreatitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021532167A JP2021532167A (ja) | 2021-11-25 |
| JP2021532167A5 true JP2021532167A5 (https=) | 2022-05-30 |
Family
ID=68770590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021518029A Pending JP2021532167A (ja) | 2018-06-05 | 2019-06-04 | 膵炎を治療するための組成物及び方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11679146B2 (https=) |
| EP (1) | EP3801620A4 (https=) |
| JP (1) | JP2021532167A (https=) |
| CN (1) | CN112512574A (https=) |
| AU (1) | AU2019282132A1 (https=) |
| CA (1) | CA3102032A1 (https=) |
| MX (1) | MX2020013155A (https=) |
| TW (1) | TW202015727A (https=) |
| WO (1) | WO2019236528A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11597744B2 (en) | 2017-06-30 | 2023-03-07 | Sirius Therapeutics, Inc. | Chiral phosphoramidite auxiliaries and methods of their use |
| US11679146B2 (en) | 2018-06-05 | 2023-06-20 | Anji Pharmaceuticals Inc. | Compositions and methods for treating pancreatitis |
| EP4268817A4 (en) * | 2020-07-01 | 2024-07-10 | Min Chen | USE OF A PCSK9 INHIBITOR IN THE PREPARATION OF A DRUG FOR THE TREATMENT OF MULTIPLE DISEASES |
| CN114250194B (zh) * | 2021-11-30 | 2023-04-11 | 四川大学华西医院 | 一种急性胰腺炎细胞模型的构建方法和用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5856487A (en) | 1996-02-14 | 1999-01-05 | National Institute Of Immunology | Application of protoberberine alkaloid, berberine, an immunosuppressive agent |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| CN101467999A (zh) | 2007-12-25 | 2009-07-01 | 郑州后羿制药有限公司 | 一种盐酸小檗碱复方制剂 |
| NZ588033A (en) | 2008-03-20 | 2012-11-30 | Carolus Therapeutics Inc | Methods of treating a mif-mediated disorder |
| CN101829113B (zh) | 2009-07-14 | 2012-12-12 | 武汉大学 | 黄连素在治疗或预防流感病毒药物中的应用 |
| CN102725311A (zh) | 2009-09-23 | 2012-10-10 | 卡罗勒斯治疗公司 | 治疗发炎的方法 |
| AR089853A1 (es) | 2012-02-01 | 2014-09-24 | Boehringer Ingelheim Int | Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso |
| US20150140005A1 (en) | 2012-05-17 | 2015-05-21 | Cyon Therapeutics Inc. | Methods and Uses for Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors |
| CN104815316A (zh) | 2015-05-25 | 2015-08-05 | 苗怡文 | 一种治疗急慢性胰腺炎的中药制剂及其制备方法 |
| EP3400069A4 (en) | 2016-01-04 | 2019-09-25 | Cour Pharmaceuticals Development Company Inc. | Particles for the Encapsulation of Fusion Proteins with Bundled Epitopes |
| WO2018007999A1 (en) | 2016-07-08 | 2018-01-11 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
| CN107468687A (zh) | 2017-09-05 | 2017-12-15 | 吴蕾 | 黄连素作为细胞m3受体抑制剂的用途 |
| US11679146B2 (en) | 2018-06-05 | 2023-06-20 | Anji Pharmaceuticals Inc. | Compositions and methods for treating pancreatitis |
-
2019
- 2019-06-04 US US15/734,461 patent/US11679146B2/en active Active
- 2019-06-04 CN CN201980037654.2A patent/CN112512574A/zh active Pending
- 2019-06-04 MX MX2020013155A patent/MX2020013155A/es unknown
- 2019-06-04 EP EP19815628.3A patent/EP3801620A4/en not_active Withdrawn
- 2019-06-04 CA CA3102032A patent/CA3102032A1/en active Pending
- 2019-06-04 AU AU2019282132A patent/AU2019282132A1/en not_active Abandoned
- 2019-06-04 WO PCT/US2019/035310 patent/WO2019236528A1/en not_active Ceased
- 2019-06-04 JP JP2021518029A patent/JP2021532167A/ja active Pending
- 2019-06-05 TW TW108119591A patent/TW202015727A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021532167A5 (https=) | ||
| Korfei et al. | Targeting histone deacetylases in idiopathic pulmonary fibrosis: a future therapeutic option | |
| Li et al. | Fibronectin induces epithelial-mesenchymal transition in human breast cancer MCF-7 cells via activation of calpain | |
| Jara et al. | Matrix metalloproteinase (MMP)-19-deficient fibroblasts display a profibrotic phenotype | |
| Saito et al. | HDAC8 inhibition ameliorates pulmonary fibrosis | |
| Ling et al. | Ankyrin repeat domain 1 protein: a functionally pleiotropic protein with cardiac biomarker potential | |
| Hot et al. | IL-17 and tumour necrosis factor α combination induces a HIF-1α-dependent invasive phenotype in synoviocytes | |
| AU2020291533B2 (en) | Methods of rejuvenating aged tissue by inhibiting 15-hydroxyprostaglandin dehydrogenase (15-PGDH) | |
| Zhao et al. | YAP1 is essential for osteoclastogenesis through a TEADs-dependent mechanism | |
| Ma et al. | Knockdown of LOXL1 inhibits TGF-β1-induced proliferation and fibrogenesis of hepatic stellate cells by inhibition of Smad2/3 phosphorylation | |
| Xu et al. | NTN4 is associated with breast cancer metastasis via regulation of EMT-related biomarkers | |
| Ma et al. | Human U87 astrocytoma cell invasion induced by interaction of βig-h3 with integrin α5β1 involves calpain-2 | |
| Nguyen et al. | Commutators of PAR-1 signaling in cancer cell invasion reveal an essential role of the Rho–Rho kinase axis and tumor microenvironment | |
| WO2013007763A9 (en) | MODULATORS OF THE NLRP3 INFLAMMASOME IL-1ß PATHWAY FOR THE PREVENTION AND TREATMENT OF ACNE | |
| Cho et al. | Protein phosphatase 1B dephosphorylates Rho guanine nucleotide dissociation inhibitor 1 and suppresses cancer cell migration and invasion | |
| RU2014132108A (ru) | Slit-robo сигналинг для диагностики и лечения заболевания почек | |
| Takahashi et al. | Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity | |
| US9957295B2 (en) | Peptides inhibiting cold-inducible RNA binding protein activity | |
| JP2010507666A5 (https=) | ||
| EP4419658A1 (en) | Methods and compositions for improving neuromuscular junction morphology and function | |
| Lamour et al. | Selective osteopontin knockdown exerts anti‐tumoral activity in a human glioblastoma model | |
| Li et al. | Cinnamic hydroxamic acid inhibits the proliferation of gastric cancer cells via upregulation of miR 145 expression and down-regulation of P13K/Akt signaling pathway. | |
| de Souza et al. | Mast cell proteases 6 and 7 stimulate angiogenesis by inducing endothelial cells to release angiogenic factors | |
| Giang Ho et al. | RhoGDIα-dependent balance between RhoA and RhoC is a key regulator of cancer cell tumorigenesis | |
| JP2009538600A (ja) | 癌治療の標的としてのｄｕｂ３ |